Core Viewpoint - Xeriant, Inc. has published a video demonstrating the effectiveness of its nanotech fire-retardant, showcasing its performance in a fire test that highlights the durability and resistance of its NEXBOARD™ technology [1][4]. Group 1: Product Performance - The video features a 15-minute fire test comparing treated and untreated plastic boards, illustrating the superior performance of Xeriant's flame retardant nanotechnology [2][3]. - The untreated board degrades quickly, while the treated board withstands direct flames exceeding 2,500 degrees Fahrenheit for at least 15 minutes [3]. Group 2: Technology Overview - NEXBOARD™ is a patent-pending composite panel made primarily from recycled plastic and fiber waste, designed to outperform traditional materials like drywall and plywood in terms of fire, water, mold, and insect resistance [4][6]. - The company aims to share additional fire test videos and is coordinating a production run with a manufacturing partner for certification testing [5]. Group 3: Company Mission - Xeriant, Inc. focuses on the discovery, development, and commercialization of disruptive technologies in advanced materials and aerospace, seeking partnerships and acquisitions to accelerate its mission [6].

SINGAPORE, April 30, 2025 (GLOBE NEWSWIRE) -- INNEOVA Holdings Limited (Nasdaq: INEO, "INNEOVA Holdings" or the "Company" or the "Group"), a leading Singapore-based provider of high-quality Original Equipment Manufacturer ("OEM"), third-party branded and in-house branded replacement parts for motor vehicles and non-vehicle combustion engines, today announced that it has completed the acquisition of INNEOVA Engineering Pte. Ltd. ("INNEOVA Engineering"), a Singapore-based engineering solutions provider. This ...

Universal Digital Inc. (Formerly Minas Metals Ltd.) Announces Completion of Change of Business, Including Name Change, Ticker Symbol LFG, Strategic Acquisitions, and Divestment of Non-Core AssetsApril 30, 2025 7:52 AM EDT | Source: Universal Digital Inc.Vancouver, British Columbia--(Newsfile Corp. - April 30, 2025) - Universal Digital Inc. (CSE: LFG) ("Universal Digital" or the "Company") (formerly Minas Metals Ltd.) is pleased to announce that, further to its news releases dated January 27, 2 ...

Ribbon Communications (RBBN) Q1 2025 Earnings Call April 29, 2025 09:19 PM ET Speaker0 Greetings, and welcome to the Ribbon Communications First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Joni Roberts, Chief Marketing Officer. Please go ahead. Speaker1 Good a ...

WASHINGTON, April 29, 2025 (GLOBE NEWSWIRE) -- Verizon today announced the launch of its first Government Cloud-Managed Software Defined Wide Area Network (SD WAN) product. Built on Verizon’s Federal Risk and Authorization Management Program (FedRAMP) High Ready Government Cloud Platform for U.S. federal agencies, the new offering is highlighted by the platform’s first SaaS Managed SD WAN solution. This innovative offering, already FedRAMP High Ready and built to NIST 800-53 controls, provides Federal agenc ...

NOV Inc. (NOV) reported first-quarter 2025 adjusted earnings of 19 cents per share, which missed the Zacks Consensus Estimate of 25 cents. The bottom line decreased from the year-ago quarter’s 30 cents. This underperformance can be attributed to margin pressures on projects within its Energy Equipment segment. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) The oil and gas equipment and services company’s total revenues of $2.1 billion marginally beat the Zacks Consensus Estimate b ...

Core Insights - Zymeworks Inc. has received FDA approval for Ziihera (zanidatamab-hrii) targeting HER2-positive biliary tract cancer, marking a significant milestone in its biotechnology journey [1] Company Overview - Zymeworks Inc. has been active in the biotechnology sector for over a decade, facing both successes and challenges in drug development [1] - The company focuses on high-growth opportunities within sectors that are expected to experience exponential expansion [1] Investment Perspective - The analysis emphasizes the importance of innovation and disruptive technologies in generating substantial returns, aligning with the company's strategic direction [1]

MUMBAI, India and EDISON, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Trigyn Technologies Ltd. (BSE: 517562, NSE: TRIGYN), Trigyn Technologies, Inc., and its subsidiaries and affiliates are pleased to announce the appointment of Vikram Chandna as its Chief Executive Officer effective immediately. Vikram will be based in the USA. In his role as CEO, Vikram will provide strategic leadership to Trigyn Technologies. He will drive the strategic growth and transformation initiatives, focusing on achieving scalable p ...

Core Insights - Oramed Pharmaceuticals has made a strategic investment in Alpha Tau Medical, acquiring approximately 14.1 million shares at a price of $2.612 per share, aimed at supporting Alpha Tau's innovative cancer therapy technology [1][2] - The partnership combines Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology, enhancing both companies' capabilities in therapeutic delivery [1][3] - Oramed will provide strategic guidance and capital markets expertise to Alpha Tau through a three-year service agreement, which includes appointing two directors to Alpha Tau's Board [2][3] Company Overview - Oramed Pharmaceuticals specializes in oral delivery solutions for drugs typically administered via injection, utilizing its proprietary Protein Oral Delivery (POD™) technology to enhance drug integrity and absorption [4] - Alpha Tau Medical, founded in 2016, focuses on the research and development of the Alpha DaRT® technology for treating solid tumors, initially developed by professors from Tel Aviv University [5] Strategic Goals - The collaboration is expected to accelerate Alpha Tau's clinical trials across four indications in the U.S., expand manufacturing capacity, and enhance commercialization efforts [1][2] - Both companies share a vision of transforming therapeutic delivery methods, with Oramed focusing on oral administration and Alpha Tau on targeted radiation therapy [3]

G-III Apparel Group, Ltd. (GIII) is successfully transforming its business by prioritizing owned brands, boosting profitability and brand control while reducing dependence on licensed labels. Strong growth from key brands like DKNY and Karl Lagerfeld, strategic digital investments and aggressive international expansion are positioning the company for sustainable, long-term success. Moreover, its focus on innovation, global reach and operational efficiency continues to drive strong momentum into fiscal 2026 ...